About Us

Sam Grant founded Unicorn Pacific Marketing with his father, Sam Grant Sr., nearly 40 years ago. Their mission was to manufacture and distribute Immune¹² — which cured Sam Grant Sr.’s terminal stomach cancer in 1962 — and help other people around the globe who are facing a cancer diagnosis. Prior to forming PMB, Sam took Immune¹² through US-based FDA clinical trials for multiple myeloma and was granted Orphan Drug designation in 2012. It is one of a handful of natural products to have orphan designation to treat specific cancer patients.

Also on the Advisory Board

After seeing Immune¹²’s positive results with brain cancer, Alan felt a profound responsibility to co-found PMB to help others in need. For over 50 years, Alan has been a leader in Connecticut’s building and development industry. As director and CEO of the Alan Temkin Group, he has partnered with multiple companies to build more than 1,500 new homes across the state, along with land and infrastructure development. He is on the Board of Directors for Brooker Memorial, an institution dedicated to improving the lives of children, and has served as President of the Northwestern Connecticut Chamber of Commerce.

Also on the Advisory Board

From the front line to the C-suite, James Sok brings medical industry insight and structured professionalism to PMB. After an early career as a pharmacist, he went onto serve at the highest levels of healthcare leadership, with a track record of improving profitability, visibility and performance at health systems along the East coast. He is a former president and CEO of numerous hospitals, including Sharon Hospital in Sharon, CT, and Sheltering Arms Corporation in Richmond, VA. He also served as executive vice president of Good Shepherd Rehabilitation Network Healthcare, a regional rehabilitation leader with more than 70 locations in Pennsylvania and New Jersey.

Ray Oneglia is a skilled businessman and expert in the construction and materials industries. Through astute acquisitions and joint venture partnerships, he has helped grow his family business, O&G Industries, into a nationally-recognized entity. He is a trusted partner for industry leaders like Tutor Perini, where he serves on the board of directors. He is also a respected resource on local and national policy, with key roles in organizations like the Connecticut Construction Industries Association, the Hudson Institute and the Business Executives for National Security.

Chris Wilson is a financial and business expert who is committed to investing in the well-being of others. Before retirement, he served for almost 30 years as senior partner at the investment firm Stonehill Capital Management, building it from less than $100 million in assets to over $3.5 billion. He is the founder and trustee of the Wilson Sheehan Foundation, which strives to build educational, economic and other opportunities for people living in low-income homes and communities.

Peter Jerin is a former international business executive known for his business prowess and financial acumen. He had a long, diverse career across eight divisions on three continents with General Electric. His experience includes managing the team that built the very first magnetic resonance imaging (MRI) machine, Managing Director for GE and Malaysia Airlines successful joint venture, and executive leader of teams across 14 EU countries. He completed his executive corporate career at Gulfstream Aerospace successfully leading global procurement teams that supported current and new aircraft design and production. In addition to his expertise in organizational design and business development, Peter also has a cum laude degree in Industrial Engineering where he was selected for Who’s Who in American Colleges and Universities.

Daniel McIntyre, a former healthcare executive who leads recruitment for PMB’s medical oncology team, is known for innovating. As a healthcare leader, he piloted strategic transformations at numerous Connecticut health providers. Most recently, that included a 20-year term as president and CEO of Charlotte Hungerford Hospital, where he oversaw the successful merger with Hartford Healthcare. With a background in engineering, Dan has also contributed to numerous inventions in aerospace, machine tool technologies and electromechanics.

David Harburger is a patent attorney working closely with life sciences clients from the early stages of formation and beyond to align their intellectual property (IP) strategy with their business goals. He advises on patent preparation and prosecution, patent portfolio management, freedom-to-operate, patent invalidity, non-infringement, IP and clinical strategy coordination, and IP due diligence matters. David has deep familiarity with patent law issues specific to life sciences-based technologies, including biochemistry, bioenergy systems, cell signaling, diagnostics, genetics, immunology, microbiome, nanoparticle carriers, nucleic acids, synthetic biology, and therapeutics. Having co-founded biotech companies, David brings an entrepreneur’s perspective to help clients build up IP as an asset while navigating a path to market. He has architected IP strategies for groundbreaking emerging technology companies to align with their entry into the public market, M&A, and partnering activities. David also advises investors in IP-related matters in financing rounds.

Michael Magnifico, MD, holds three board certifications: internal medicine, medical oncology and hematology. During his decades of clinical practice, he directly cared for patients throughout northwest Connecticut, notably at Sharon Hospital, Charlotte Hungerford Hospital and New Milford Hospital; and served as medical director of the VNA Hospice in Torrington for 30 years.

Dr. Magnifico received his baccalaureate of medical sciences from Dartmouth Medical School and obtained his medical degree from Columbia University College of Physicians and Surgeons. His residencies in medicine and anatomic pathology were at Columbia Presbyterian Medical Center, and he completed his fellowships in medical oncology and hematology at the Yale School of Medicine.

Dr. Santosh Kesari is a distinguished neurologist and neuro-oncologist renowned for his contributions to brain cancer research and treatment. He serves as the Chair and Professor of the Department of Translational Neurosciences at the Saint John’s Cancer Institute.

An internationally recognized scientist and clinician, Dr. Kesari has authored over 250 scientific publications, reviews, and books. His research focuses on cancer stem cells and their role in brain tumor formation and treatment resistance. He is also the inventor on several patents and has founded and advised numerous biotech startups focused on cancer and neurosciences.

Throughout his career, Dr. Kesari has received numerous accolades, such as being ranked among the top 1% of neuro-oncologists and neurologists in the nation by Castle Connolly Medical Ltd. He was also honored with an Innovation Award by the San Diego Business Journal.

Andrew S. Verderame, MBA, RAC leads the FDA Regulatory LLC Consulting group and is our Strategic Regulatory Affairs Advisor as we plan for and conduct our interactions with US FDA. He also serves on the Board of Directors at ViTalent Health Sciences. Most recently he was CEO at SciLucent, LLC and President/Partner with PharmaLex US, both highly respected pharmaceutical consulting firms. He has been active in the pharmaceutical industry since 1985 and previously held senior regulatory affairs positions at Merck Serono, Alexion and Bayer HealthCare. Andrew has personally led over one hundred meetings with FDA, managed multi-site global regulatory teams for both large and small pharmaceutical companies, led preparations and presentations to FDA Advisory Committees, with successful outcomes, and was responsible for numerous New Drug Application approvals from US FDA.

Andrew Satterlee, PhD, is an Assistant Professor and Founding Director of the Screening Live Cancer Explants Program and Core Facility based within Eshelman Innovation, an academic innovation institute at UNC focused on translating groundbreaking ideas toward patients.  Dr. Satterlee is himself a brain cancer survivor whose rare, heterogeneous tumor lacked a clear treatment strategy.  Today, his program focuses on developing functional precision medicine models that directly treat living patient tumor tissues outside the body just after they have been removed in the operating room to guide drug development and clinical decision-making.